Clinical trial designs for rare diseases part 2 of 2, trial protocols /

Viečča ollesdeavstta

Surrogate endpoints, part 1 from definition to meta-analytic framework /

Viečča ollesdeavstta
Series

Surrogate endpoints, part 2 further developments /

Viečča ollesdeavstta
Series

Patient heterogeneity in dose-finding trials part 1, methods for 2 groups/

Viečča ollesdeavstta
Series

Patient heterogeneity in dose-finding trials part 2, more than 2 groups /

Viečča ollesdeavstta
Series

Implementation of adaptive methods in early phase clinical trials

Viečča ollesdeavstta
Series

Adaptation in likelihood trials

Viečča ollesdeavstta
Series

The Salford lung study in COPD

Viečča ollesdeavstta
Series

Adaptive clinical trial design randomization /

Viečča ollesdeavstta
Series

Frequentist approaches sample size in adaptive clinical designs /

Viečča ollesdeavstta
Series

Adaptive clinical trials overview, part 1 of 2 /

Viečča ollesdeavstta
Series

Adaptive clinical trials overview, part 2 of 2 /

Viečča ollesdeavstta
Series

Case studies of adaptive early phase trials

Viečča ollesdeavstta
Series

Bayesian adaptive designs for clinical trials

Viečča ollesdeavstta
Series

Survival analysis

Viečča ollesdeavstta
Series

Randomization in N-of-1 clinical trials is it possible to draw causal inferences from single-patient data /

Viečča ollesdeavstta
Series

The dynamic interactions between cellular-molecular physiology and the environment part 4, Future directions in cellular-molecular evolutionary biology /

Viečča ollesdeavstta
Series

Immune checkpoint blockade in renal cell carcinoma

Viečča ollesdeavstta
Series (Immunotherapy of cancer)
Series (Kidney in health and disease)

Regulatory considerations for vaccine development, talk 2 clinical regulatory considerations (part 1 of 2) /

Viečča ollesdeavstta
Series

Regulatory considerations for vaccine development, talk 1 chemistry, manufacturing and control /

Viečča ollesdeavstta
Series